|
|
 |
LYNPARZA Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
MAGNESIUM HYDROXIDE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
MAGNESIUM ALUMINUM SILICATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ANHYDROUS DIBASIC CALCIUM PHOSPHATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ACESULFAME POTASSIUM Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ANHYDROUS CITRIC ACID Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|